

REVIEW ARTICLE

Mycoplasmas in diseases of humans

JOANNE E. EMBREE, M SC; JUAN A. EMBIL, MD, PH D, FRCP[C]

The roles of *Mycoplasma pneumoniae*, *M. hominis* and *Ureaplasma urealyticum* in diseases of humans are currently under investigation. *M. pneumoniae*, which causes primary atypical pneumonia, is a well established pathogen of the respiratory tract. Complications of infection by this organism are also being recognized; they include disorders of the hematopoietic, cardiovascular, central nervous, musculoskeletal, cutaneous and gastrointestinal systems. The roles of the genital mycoplasmas *M. hominis* and *U. urealyticum* are controversial but may include infections of the genitourinary tract and in pregnancy as well as diseases of the newborn, such as neonatal pneumonia and meningitis. In this review atypical pneumonia due to *M. pneumoniae* is described and the role of mycoplasmas in other diseases is discussed.

Le rôle de *Mycoplasma pneumoniae*, *M. hominis* et *Ureaplasma urealyticum* comme source de maladies chez l'humain fait présentement l'objet de recherches. *M. pneumoniae*, qui cause principalement une pneumonie atypique, est un microorganisme pathogène bien connu des voies respiratoires. Les complications d'une infection due à cet organisme sont aussi en voie d'être reconnues; elles incluent des atteintes des systèmes hématopoïétique, cardiovasculaire, nerveux central, musculosquelettique, cutané et gastrointestinal. Les rôles des mycoplasmes d'origine génitale *M. hominis* et *U. urealyticum* prêtent à controverse; ils peuvent inclure des infections des voies génitourinaires, des infections observées durant la grossesse, de même que des maladies du nouveau-né telles que pneumonie et méningite. Dans cet article de revue on décrit la pneumonie atypique due à *M. pneumoniae* et on discute le rôle des mycoplasmes dans d'autres maladies.

Mycoplasmas are the smallest known bacteria that can form recognizable colonies on cell-free media. Their minimum reproductive size, approximately 100 nm, is similar to that of the largest viruses. However, unlike viruses, mycoplasmas possess both deoxyribonucleic acid and ribonucleic acid for replication. They are pleomorphic, lacking a cell wall, but are not genetically related to the other types of bacteria

with complete or partial absence of a cell wall — L-forms, spheroplasts and protoplasts. Penicillins are useless in the treatment of disease caused by these organisms, but tetracyclines are effective.^{1,2}

Mycoplasmas constitute the class called Mollicutes. The only order in this class, Mycoplasmatales, is currently divided into two families: the Mycoplasmataceae, with *Mycoplasma* and *Ureaplasma* genera, which require sterols for growth, and the

Acholeplasmataceae, which do not. A third family, the Spiroplasmataceae, with the genus *Spiroplasma*, is proposed for the mycoplasmas of plants and insects. The thermoplasmas, which have been isolated from acidic refuse piles, and the anaeroplasmataceae, which have been found in the anaerobic rumen of cows and sheep, are also considered members of the Mollicutes, but their exact taxonomic position has not yet been decided.³

Of the 59 species of Mycoplasmataceae described to date, 10 are found in the human body: *M. buccale*, *M. faucium*, *M. fermentans*, *M. hominis*, *M. lipophilum*, *M. orale*, *M. pneumoniae*, *M. primatum*, *M. salivarium* and *U. urealyticum*.³ Of these, only *M. hominis*, *M. pneumoniae* and *U. urealyticum* are suspected of being pathogenic. In this paper we review, with the aid of the English literature, the known or suspected roles of these three mycoplasmas in disease of eight body systems of humans.

Respiratory system

In the respiratory system the most common mycoplasma of clinical significance is *M. pneumoniae* (Eaton's agent), which is responsible for various respiratory syndromes,

From the departments of microbiology and pediatrics, Dalhousie University, Halifax

Reprint requests to: Dr. Juan A. Embil, Infectious diseases research laboratory, Izaak Walton Killam Hospital for Children, 5850 University Ave., Halifax, NS B3J 3G6

Reproduced on the cover of this issue of the Journal is a Carl Zeiss Nomarski interference contrast photomicrograph of colonies of *Mycoplasma hominis* isolated on agar; the final magnification is $\times 385$. The photomicrography was performed by Mr. F. Stefani of Dalhousie University's photographic unit.

including primary atypical pneumonia.⁴ Other less common mycoplasmas found in this system are *M. buccale*, *M. faucium*, *M. fermentans*, *M. lipophilum*, *M. orale* and *M. salivarium*, which are generally believed to be commensals.^{3,5} *M. hominis* and *U. urealyticum* have also been found in the respiratory system in association with neonatal pneumonia following exposure in utero or during birth.^{6,7}

Epidemiologic aspects

M. pneumoniae is responsible for epidemics of respiratory illness every 2 to 6 years^{8,9} and may account for 10% to 50% of diagnosed cases of pneumonia.⁹⁻¹¹ The peak occurrence of these illnesses is in early fall and winter, although *M. pneumoniae* is endemic throughout the year and may be the most common cause of respiratory illnesses in summer.⁹ Children from 5 to 19 years of age are most often affected; those less than 5 years of age rarely have severe symptoms.^{8,12-14} Pneumonia occurs in 3% to 10% of those known to be infected, most frequently in persons between 10 and 30 years of age.⁹ Since the illness is often mild and only the more severe cases come to medical attention, the incidence of *M. pneumoniae* infection is probably underestimated. The incubation period is 2 to 3 weeks¹⁵ and, although the carrier state may last up to 5 months, the organism appears to be spread by coughing during the 2 to 3 weeks of the acute stage of the illness.⁴ Close contact is needed for transmission, so the illness is more frequent among members of a family, military recruits, schoolchildren and other "closed" populations.⁹

Pathophysiologic findings

Although primary atypical pneumonia is usually mild, fatal cases have been reported; pathological examination has shown congested lungs with numerous small grey nodules, hyperemic respiratory mucosa, a mononuclear alveolar exudate and interstitial infiltration with plasma cells.^{16,17} In one proven case of infection due to *M. pneumoniae*, the walls of the bronchioles were thickened by edema and infiltration by macrophages, lymphocytes and

plasma cells.¹⁷ In another case these features were accompanied by severe bronchiectasis, with ulceration and fibrosis of the bronchial walls.¹⁸

In mycoplasmal pneumonia various immunologic abnormalities may occur: autoantibody formation to lung, smooth muscle, lymphocytes and other tissues;⁹ decreased tracheobronchial clearance of inhaled foreign particles;¹⁹ and diminished reactivity to tuberculin in a sensitized individual.²⁰ Because severe symptoms are rare despite evidence of exposure in children less than 5 years of age, pneumonia is thought to result from hypersensitivity due to repeated exposure.¹³

Signs and symptoms

The illness begins with headache, fevers, chills, malaise and anorexia. A sore throat follows; the accompanying cough is dry at first, but after a week mucoid sputum is produced.⁴ Earache occurs in about 30% of cases, but otitis externa, otitis media and bullous myringitis are rare.⁹ Rhonchi, rales and wheezing are common,¹⁰ as is substernal soreness, while pleurisy and hemoptysis are unusual.²¹

Radiologic features

Generally the physical findings are much less striking than the roentgenographic findings, which, however, are not diagnostic of mycoplasmal pneumonia. In 90% of cases the lower lobe of one of the lungs shows a patchy or reticular interstitial infiltrate extending from hilum to periphery. A mixed interstitial and acinar pattern is sometimes seen. Involvement of the upper or middle lobe, bilateral involvement, hilar adenopathy and lobar consolidation rarely occur.^{9,11,22}

Pleural effusions are seen occasionally;²³ they are sterile serous or serosanguineous proteinaceous exudates with a specific gravity of 1.015 to 1.028.⁹

Laboratory diagnosis

The diagnosis of pneumonia due to *M. pneumoniae* is based upon recovery of the organism from throat swabs, nasopharyngeal aspirations, sputum or other samples from the respiratory system or diagnostic rises in antibody titres, or

both, along with the clinical and radiologic features.

M. pneumoniae is difficult to isolate and may take up to 3 weeks to grow. Therefore, isolation is usually attempted only for research purposes or in very special circumstances.

Antibody titres can be determined by several methods: complement fixation, metabolic inhibition, mycoplasmacidal complement-dependent antibody, radioimmunoprecipitation, counterimmunoelectrophoresis and indirect hemagglutination.⁹

A nonspecific diagnostic aid is the presence of cold agglutinins, IgM antibodies that are found in 33% to 75% of cases.⁹ These agglutinins also appear in infectious mononucleosis, rubella, influenza and adenovirus infections, as well as in a number of noninfectious conditions, such as some of the hemolytic anemias, blood dyscrasias, liver diseases, certain allergic conditions and peripheral vascular disorders.^{9,24} They are likely to occur with pneumonia and have been thought to reflect its severity. However, they are less common in children.¹⁵

Blood counts and levels are usually normal; however, there may be an increase in the neutrophil count, with a shift to less mature cells, and the erythrocyte sedimentation rate is often raised.^{11,15}

Treatment

Therapy with erythromycin or tetracycline relieves the symptoms but does not eliminate the organism, thereby leaving the immune response intact.^{4,15} However, tetracycline is not recommended for children or pregnant women. Left untreated, the acute illness usually resolves within 2 to 3 weeks. With antibiotic therapy the symptoms disappear or are markedly reduced within 3 to 4 days and the radiologic abnormalities and cough are gone within 2 weeks.⁴ The response to therapy differentiates atypical pneumonia caused by *M. pneumoniae* from that caused by viruses.

Complications

M. pneumoniae, along with the respiratory viruses, has been associated with exacerbations of bron-

chial asthma²⁵ and with chronic bronchitis.²⁶ The symptoms are more severe in children with some hemoglobinopathies,²⁷ and immunodeficiency may alter the symptoms drastically.²⁸ Recently the organism was associated with Legionnaires' disease in one patient.²⁹ Infection with *M. pneumoniae* does not usually predispose to secondary infection by more pathogenic organisms.⁹ However, a possible respiratory complication may be the Swyer-James syndrome — residual hyperlucent areas of the lung.³⁰

Complications of *M. pneumoniae* infection have also involved the hematopoietic, cardiovascular, central nervous, musculoskeletal, cutaneous and gastrointestinal systems.³¹

Hematopoietic system

The production of cold agglutinins by *M. pneumoniae* is responsible, along with infection by this organism, for a number of fairly rare hematologic complications, such as hemolytic anemia, acrocyanosis and thrombocytopenia.^{9,31} Disseminated intravascular coagulation has been reported; in two instances it led to acute renal failure and in one symmetric peripheral gangrene.³²⁻³⁴ Treatment includes administration of heparin and prednisone along with erythromycin or tetracycline and transfusion of warmed erythrocytes or type i erythrocytes from adults.⁹

Cardiovascular system

M. pneumoniae infection has been serologically associated with pericarditis, myopericarditis, myocarditis, hemopericardium, complete heart block, congestive heart failure and death.^{9,34-36} The organism has also been isolated from pericardial fluid.³⁷

Cardiovascular problems occur in either the acute or the recovery phase of *M. pneumoniae* infection. Consequently, two separate mechanisms of damage may be at work. Heart disease in the acute phase may be due to the toxic effects of the organism and can be treated with antimicrobial drugs. In the recovery phase the damage may be

due to immunologic mechanisms.³⁸ Residual effects are rare.

M. pneumoniae infection should be considered when heart failure occurs during or after an upper respiratory tract infection.³⁸

Central nervous system

M. pneumoniae infection has also been associated with neurologic syndromes, such as psychosis in the elderly, meningitis, meningoencephalitis, transverse myelitis, hemiplegia, ascending paralysis, cranial nerve palsy, brain stem encephalitis and poliomyelitis-like illness. The organism is identified either by isolation at the time of the neurologic illness or by a diagnostic rise in antibody titres.^{9,38-40} A respiratory illness may or may not occur before the onset of neurologic symptoms.

The frequency of neurologic complications has not been accurately determined. Furthermore, the pathogenesis of the association between *M. pneumoniae* and neurologic symptoms is not clear, but it is most likely due to an immunologic mechanism. *M. pneumoniae* is rarely isolated from the cerebrospinal fluid and produces no distinctive symptoms. The diagnosis is based primarily on a rise in antibody titres. Although antimicrobial therapy is not effective, patients usually recover completely.

M. hominis was reported as the causative agent isolated from the cerebrospinal fluid in cases of neonatal meningitis^{41,42} and from a brain abscess in one case.⁴³ Therefore it should be considered in cases of neonatal meningitis if the results of Gram-staining are negative, no growth occurs on conventional culture media and there is a history of possible genital tract infection in the mother.^{41,42}

Musculoskeletal system

M. pneumoniae infection is often accompanied by nonspecific arthralgias or myalgias during the acute phase. Occasionally it leads to migratory polyarthropathy affecting middle-sized joints, in which combinations of joint swelling, morning stiffness, "gelling" with stiffness

after inactivity and considerable functional disability may occur. Symptoms may last up to a year but will eventually disappear.^{44,45}

M. hominis has been isolated from the synovial fluid of an inflamed hip joint in a patient with septic arthritis following childbirth. The condition was believed to have been caused by septicemia after delivery and was cured by the administration of tetracycline.⁴⁶ In view of this case *M. hominis* should be considered in patients with postpartum arthritis whose condition does not respond to penicillin.

U. urealyticum was isolated from the synovial fluid of an acutely inflamed joint in a patient with hypogammaglobulinemia; treatment with tetracycline was successful.⁴⁷

Cutaneous system

A wide variety of nondistinctive rashes frequently occur with or after infection by *M. pneumoniae*. These have been described as "discrete or confluent, pruritic or non-pruritic erythematous macular, maculopapular, urticarial, vesicular, bullous, or petechial lesions. Some of these rashes are scaling, scarlatiniform, pityriasis rosea-like, Henoch-Schönlein purpura or erythema nodosa."⁹ Reports of the Stevens-Johnson syndrome (severe erythema multiforme) associated with *M. pneumoniae* infection have been numerous.^{14,48}

The exact mechanism by which the rashes are produced is unknown, but they may be due to increased sensitivity to antibiotics. The rash usually lasts for 7 to 10 days.⁹

Gastrointestinal system

During the acute phase of infection by *M. pneumoniae* prolonged anorexia, nausea, vomiting and diarrhea occur in 12% to 44% of patients.⁹ *M. pneumoniae* infection, as demonstrated by a diagnostic rise in antibody titres, has been documented in patients with acute pancreatitis,⁴⁹ but the exact nature of the relationship is obscure.

Genitourinary system

M. hominis (Figs. 1A and 1B)

and *U. urealyticum* (Fig. 2) are the genital mycoplasmas of clinical importance for humans. *M. fermentans*, the other genital mycoplasma, is rarely found and has not yet been associated with any pathologic condition.¹

About one third of healthy infants are colonized at birth with *U. urealyticum*, presumably acquired during passage through the birth canal. *M. hominis* is much less common. Rates of isolation of both mycoplasmas decrease during the first year of life and are extremely low before puberty. Recolonization is associated with sexual activity and increases with the number of partners.⁵⁰⁻⁵³ In a study of healthy women McCormack and colleagues⁵¹ isolated mycoplasmas from the genital tract of 37% of the subjects who had had one sexual partner but 75% of those who had had more than three partners. Similar isolation rates have been found for healthy men.⁵²

M. hominis and *U. urealyticum* have been associated with a number of diseases of the genitourinary system, problems in pregnancy and diseases of the newborn.

Thomsen⁵⁴ isolated *M. hominis* from the bladder urine significantly more often in patients with chronic pyelonephritis than in those without. The possible causal relation between the organism and this condition was demonstrated by both the isolation of the mycoplasma and diagnostic rises of antibody titres in acute exacerbations of the disease.

U. urealyticum splits urea and may play a role similar to that of *Proteus mirabilis* in the formation of bladder stones. No cases in humans have been documented, although *U. urealyticum* has been shown experimentally to cause such stones in rats.⁵⁵

The role of *M. hominis* and *U. urealyticum* in nongonococcal urethritis is controversial. Mycoplasmas have been isolated from men with and without this condition, although some investigators have reported a higher isolation rate, particularly for *U. urealyticum*, in those with the condition.¹ Others have reported similar rates.⁵⁶ In some instances *U. urealyticum*




FIG. 1A—Bright-field photomicrograph of colonies of *Mycoplasma hominis* isolated from female genital tract (×275).




FIG. 1B—Nomarski interference contrast photomicrograph of same field as in Fig. 1A (×275).

has been the only organism isolated from patients with nongonococcal urethritis.⁵⁷

Mycoplasmas have also been isolated from women with various diseases of the female reproductive tract. They were isolated from an abscess of Bartholin's gland, but it was not established that they had caused the abscess.⁵⁸ In vaginitis the presence of *M. hominis* may depend on that of *Trichomonas vaginalis*.^{59,60} For example, antibiotics used to eliminate *T. vaginalis* have also eliminated *M. hominis*, but the reverse has not occurred.⁵⁹ Infec-

tion by *T. vaginalis* may provide optimum conditions for the growth of *M. hominis*; however, *M. hominis* is also found alone. Both genital mycoplasmas have been isolated from inflamed fallopian tubes and from tubo-ovarian and pelvic abscesses, but only *M. hominis* appears to have instigated these infections.^{1,61} Vaginal discharge, however, cannot be attributed to *M. hominis*.⁵⁹ *M. pneumoniae* was isolated from a tubo-ovarian abscess in one patient who had had pneumonia 2 weeks earlier; the mycoplasma was thought to have spread

via the bloodstream.⁶² The exact role of these organisms in diseases of the female reproductive tract is not clear and needs controlled studies.

Opinions about the role of mycoplasmas, particularly *U. urealyticum*, in primary infertility differ markedly. Some studies have shown a significantly higher rate of isolation of *U. urealyticum* from infertile than from fertile couples,⁶³ while other studies have not.^{60,64} Colonies of T-mycoplasmas (T for tiny) have been seen attached to sperm;⁶⁵ this has led to the belief that the organism prevents fertilization by interfering with sperm function. Alternatively, pelvic inflammatory disease due to these organisms may account for the problem.^{1,61} Conception rates of 29% to 84% have been reported in couples treated with tetracycline to eliminate *U. urealyticum*,^{66,67} but these studies were not controlled. The only controlled study reported⁶⁸ showed that the increase in the rate of conception with tetracycline treatment was not significantly greater than the increase with placebo treatment.

M. hominis and *U. urealyticum* have been isolated from mother, fetus or placenta in numerous cases of spontaneous abortion;^{6,69-72} however, a causal relation has not been proved. In view of the number of healthy pregnant women who carry genital mycoplasmas and deliver healthy infants at term, and the potential hazard of tetracycline to both mother and fetus, treatment during pregnancy to eliminate mycoplasmas and prevent abortion is not advisable. Treatment before conception will not necessarily eliminate genital mycoplasmas for the duration of the pregnancy.

The isolation of genital mycoplasmas from women and their infants has been related to a lower mean birth weight,^{53,71,73,74} prematurity,⁷⁴ prolonged rupture (for more than 24 hours) of the placental membranes^{50,74,75} and inflammation of the placenta.^{6,7,74,76} Finally, genital mycoplasmas have been associated with a low-grade postpartum fever of short duration that does not usually result in significant disability.⁷⁵




FIG. 2—Nomarski interference contrast photomicrograph of colonies of *Ureaplasma urealyticum* isolated from female genital tract (×350).

Conclusion

As more physicians become aware of mycoplasmas as a possible cause of numerous conditions more information concerning their role will become available. All the mycoplasmas are susceptible to tetracycline, and *M. pneumoniae* and *U. urealyticum* are also susceptible to erythromycin. Therefore recognition and treatment to eliminate these organisms will, in most instances, significantly shorten the course of the illness and decrease the accompanying disability. At the moment the greatest problem is a lack of clinical suspicion.

We thank Mrs. Shirley W. MacDonald for her assistance in the preparation of this manuscript and Mr. F. Stefani, of Dalhousie University's photographic unit, for the photomicrographs.

References

1. MCCORMACK WM, BRAUN P, LEE Y-H, et al: The genital mycoplasmas. *N Engl J Med* 288: 78, 1973
2. LEE Y-H, MCCORMACK WM: Clinical implication of the genital mycoplasmas in obstetrics and gynecology. *J Reprod Med* 13: 123, 1974
3. LASKIN AI, LECHEVALIER HA (eds): *CRC Handbook of Microbiology*, vol 1, *Organismic Microbiology*, 2nd ed, CRC Pr, Cleveland, Ohio, 1977, pp 405-59
4. SMITH CB, OVERALL JC JR: Clinical and epidemiologic clues to the diagnosis of respiratory infections. *Radiol Clin North Am* 11: 261, 1973
5. TAYLOR-ROBINSON D: The importance of mycoplasmas in respiratory infections. *Dev Biol Stand* 28: 86, 1975
6. TAFARI N, ROSS S, NAEYE RL, et al: Mycoplasma T strains and perinatal death. *Lancet* 1: 108, 1976
7. BRUNELL PA, DISCHE RM, WALKER MB: Mycoplasma, amnionitis, and respiratory distress syndrome. *JAMA* 207: 2097, 1969
8. NOAH ND: Epidemiology of *Mycoplasma pneumoniae* infection in the United Kingdom: an analysis of reports to the Public Health Laboratory Service of England and Wales. *Infection* 4 (suppl 1): 25, 1976
9. LEVINE DP, LERNER AM: The clinical spectrum of Mycoplasma pneumoniae infections. *Med Clin North Am* 62: 961, 1978
10. IONNO JA, WESTFALL RE: Mycoplasma pneumoniae pneumonia: clinical course and complications. *Milit Med* 135: 459, 1970
11. RISKI H, ALANKO K: Mycoplasma and influenza pneumonia in a series of 214 adults. *Scand J Respir Dis [Suppl]* 89: 235, 1974
12. FOY HM, KENNY GE, MCMAHAN R, et al: Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance. *JAMA* 214: 1666, 1970
13. FERNALD GW, COLLIER AM, CLYDE WA JR: Respiratory infections due to Mycoplasma pneumoniae in infants and children. *Pediatrics* 55: 327, 1975
14. STEVENS D, SWIFT PGF, JOHNSTON PGB, et al: Mycoplasma pneumoniae infections in children. *Arch Dis Child* 53: 38, 1978
15. DENNY FW, CLYDE WA JR, GLEZEN WP: Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. *J Infect Dis* 123: 74, 1971
16. PARKER F JR, JOLLIFFE LS, FINLAND M: Primary atypical pneumonia: report of 8 cases with autopsies. *Arch Pathol* 44: 581, 1947
17. MAISEL JC, BABBITT LH, JOHN TJ: Fatal Mycoplasma pneumoniae infection with isolation of organisms from lung. *JAMA* 202: 287, 1967
18. HALAL F, BROCHU P, DELAGE G, et al: Severe disseminated lung disease and bronchiectasis probably due to Mycoplasma pneumoniae. *Can Med Assoc J* 117: 1055, 1977
19. CAMNER P, JARSTRAND C, PHILIPSON K: Tracheobronchial clearance 5-15 months after infection with Mycoplasma pneumoniae. *Scand J Infect Dis* 10: 33, 1978
20. BIBERFELD G, STERNER G: Tuberculin anergy in patients with Mycoplasma pneumoniae infection. *Scand J Infect Dis* 8: 71, 1976
21. SIMMONS BP, ABER RC: Mycoplasma pneumoniae pneumonia. Symptoms mimicking pulmonary embolism with infarction. *JAMA* 241: 1268, 1979
22. CAMERON DC, BORTHWICK RN, PHILIP T: The radiographic patterns of acute mycoplasma pneumonitis. *Clin Radiol* 28: 173, 1977
23. CHESTER A, KANE J, GARAGUSI V: Mycoplasma pneumonia with bilateral pleural effusions. *Am Rev Respir Dis* 112: 451, 1975
24. FINLAND M, PETERSON OL, ALLEN HE, et al: Cold agglutinins: occurrence of cold isohemagglutinins in various conditions. *J Clin Invest* 24: 451, 1945
25. HUHTI E, MOKKA T, NIKOSKELAINEN J, et al: Association of viral and mycoplasma infections with exacerbations of asthma. *Ann Allergy* 33: 145, 1974
26. BUSCHO RO, SEXTON D, SHULTZ PS, et al: Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. *J Infect Dis* 137: 377, 1978
27. CHUSID MJ, LACHMAN BS, LAZERSON J: Severe Mycoplasma pneumoniae and vesicular eruption in SC hemoglobinopathy. *J Pediatr* 93: 449, 1978
28. FOY HM, OCHS H, DAVIS SD, et al: Mycoplasma pneumoniae infections in patients with immunodeficiency syndromes: report of four cases. *J Infect Dis* 127: 388, 1973
29. OLDENBURGER D, CARSON JP, GUNDLACH WJ, et al: Legionnaires' disease. Association with Mycoplasma pneumoniae and disseminated intravascular coagulation. *JAMA* 241: 1269, 1979
30. STOKES D, SIGLER A, KHOURI NF, et al: Unilateral hyperlucent lung (Swyer-James syndrome) after severe Mycoplasma pneumoniae infection. *Am Rev Respir Dis* 117: 145, 1978
31. MURRAY HW, MASUR H, SENTERFIT LB, et al: The protean manifestations of Mycoplasma pneumoniae infection in adults. *Am J Med* 58: 229, 1975
32. NILSSON IM, RAUSING A, DENBERG T, et al: Intravascular coagulation and acute renal failure in a child with Mycoplasma infection. *Acta Med Scand* 189: 359, 1971
33. DE VOS M, VAN NIMMEN L, BAELE G: Disseminated intravascular coagulation during a fatal Mycoplasma pneumoniae infection. *Acta Haematol (Basel)* 52: 120, 1974
34. PICKENS S, CATTERALL JR: Disseminated intravascular coagulation and myocarditis associated with Mycoplasma pneumoniae infection. *Br Med J* 1: 1526, 1978
35. SANDS MJ JR, SATZ JE, TURNER WE, et al: Pericarditis and perimyocarditis associated with active Mycoplasma pneumoniae infection. *Ann Intern Med* 86: 544, 1977
36. MARESH H, KLIMEK JJ, QUINTILIANI R: Myocardial dysfunction and hemolytic anemia in a patient with Mycoplasma pneumoniae infection. *Chest* 71: 410, 1977
37. LEWES D, RAINFORD DJ, LANE WF: Symptomless myocarditis and myalgia in viral and Mycoplasma pneumoniae infections. *Br Heart J* 36: 924, 1974
38. JACHUCK SJ, GARDNER-THORPE C, CLARK F, et al: A brainstem syndrome associated with Mycoplasma pneumoniae infection — a report of two cases. *Postgrad Med J* 51: 475, 1975
39. DORFF B, LIND K: Two fatal cases of meningoencephalitis associated with Mycoplasma pneumoniae infection. *Scand J Infect Dis* 8: 49, 1976
40. WARREN P, FISCHBEIN C, MASCOLI N, et al: Poliomyelitis-like syndrome caused by Mycoplasma pneumoniae. *J Pediatr* 93: 451, 1978
41. WEALTHALL SR: Mycoplasma meningitis in infants with spina bifida. *Dev Med Child Neurol* 17 (suppl 35): 117, 1975
42. GEWITZ M, DINWIDDIE R, REES L, et al: Mycoplasma hominis. A cause of neonatal meningitis. *Arch Dis Child* 54: 231, 1979
43. SIBER GR, ALPERT S, SMITH AL, et al: Neonatal central nervous sys-

- tem infection due to *Mycoplasma hominis*. *J Pediatr* 90: 625, 1977
44. WEINSTEIN MP, HALL CB: *Mycoplasma pneumoniae* infection associated with migratory polyarthritides. *Am J Dis Child* 127: 125, 1974
 45. HERNANDEZ LA, URQUHART GED, DICK WC: *Mycoplasma pneumoniae* infection and arthritis in man. *Br Med J* 2: 14, 1977
 46. VERINDER DGR: Septic arthritis due to *Mycoplasma hominis* — case report and review of literature. *J Bone Joint Surg [Br]* 60: 224, 1978
 47. WEBSTER ADB, TAYLOR-ROBINSON D, FURR PM, et al: Mycoplasmal (ureaplasma) septic arthritis in hypogammaglobulinaemia. *Br Med J* 1: 478, 1978
 48. SONTHEIMER RD, GARIBALDI RA, KRUEGER GG: Stevens-Johnson syndrome associated with *Mycoplasma pneumoniae* infections. *Arch Dermatol* 114: 241, 1978
 49. FREEMAN R, MCMAHON MJ: Acute pancreatitis and serological evidence of infection with *Mycoplasma pneumoniae*. *Gut* 19: 367, 1978
 50. KLEIN JO, BUCKLAND D, FINLAND M: Colonization of newborn infants by mycoplasmas. *N Engl J Med* 280: 1025, 1969
 51. MCCORMACK WM, ALMEIDA PC, BAILEY PE, et al: Sexual activity and vaginal colonization with genital mycoplasmas. *JAMA* 221: 1375, 1972
 52. MCCORMACK WM, LEE Y-H, ZINNER SH: Sexual experience and urethral colonization with genital mycoplasmas. A study in normal men. *Ann Intern Med* 78: 696, 1973
 53. MCCORMACK WM: Genital mycoplasmal infections: their relation to prematurity and other abnormalities of reproduction. *J Clin Pathol* 29 (suppl 10): 95, 1976
 54. THOMSEN AC: The occurrence of mycoplasmas in the urinary tract of patients with chronic pyelonephritis. *Acta Pathol Microbiol Scand [B]* 83: 10, 1975
 55. FRIEDLANDER AM, BRAUDE AL: Production of bladder stones by human T mycoplasmas. *Nature* 247: 67, 1974
 56. LEE Y-H, TARR PI, SCHUMACHER JR, et al: Reevaluation of the role of T-mycoplasmas in nongonococcal urethritis. *J Am Vener Dis Assoc* 3: 25, 1976
 57. TAYLOR-ROBINSON D, CSONKA GW, PRENTICE MJ: Chlamydial and ureaplasma-associated urethritis (C). *Lancet* 1: 903, 1977
 58. DIENES L, EDSALL G: Observations on the L-organism of Klieneberger. *Proc Soc Exp Biol Med* 36: 740, 1937
 59. BERCOVICI B, PERSKY S, ROZANSKY R, et al: *Mycoplasma* (pleuropneumonia-like organisms) in vaginitis. *Am J Obstet Gynecol* 84: 687, 1962
 60. BERCOVICI B, HAAS H, SACKS T, et al: Isolation of mycoplasmas from the genital tract of women with re-
- productive failure, sterility or vaginitis. *Isr J Med Sci* 14: 347, 1978
 61. MÅRDH P-A: Increased serum levels of IgM in acute salpingitis related to the occurrence of *Mycoplasma hominis*. *Acta Pathol Microbiol Scand [B]* 78: 726, 1970
 62. THOMAS M, JONES M, RAY S, et al: *Mycoplasma pneumoniae* in a tubo-ovarian abscess (C). *Lancet* 2: 774, 1975
 63. GNARPE H, FRIBERG J: *Mycoplasma* and human reproductive failure. I. The occurrence of different mycoplasmas in couples with reproductive failure. *Am J Obstet Gynecol* 114: 727, 1972
 64. MATTHEWS CD, ELMSLIE RG, CLAPP KH, et al: The frequency of genital mycoplasma infection in human fertility. *Fertil Steril* 26: 988, 1975
 65. SCHOUB BD, JACOBS YR, HYLÉN E, et al: The role of mycoplasma in human infertility. *S Afr Med J* 50: 445, 1976
 66. KUNDSEN RB: *Mycoplasma* infections of the female genital tract, in *Progress in Gynecology*, vol 6, TAYMOR ML, GREEN T (eds), Grune, New York, 1975, pp 219-306
 67. FRIBERG J, GNARPE H: *Mycoplasma* and human reproductive failure. III. Pregnancies in "infertile" couples treated with doxycycline for T-mycoplasmas. *Am J Obstet Gynecol* 116: 23, 1973
 68. HARRISON RF, DE LOUVOIS J, BLADES M, et al: Doxycycline treatment and human infertility. *Lancet* 1: 605, 1975
 69. HARWICK HJ, PURCELL RH, IUPPA JB, et al: *Mycoplasma hominis* and abortion. *J Infect Dis* 121: 260, 1970
 70. CASPI E, SOLOMON F, SOMPOLINSKY D: Early abortion and *Mycoplasma* infection. *Isr J Med Sci* 8: 122, 1972
 71. DI MUSTO JC, BOHJALIAN O, MILLAR M: *Mycoplasma hominis* type I infection and pregnancy. *Obstet Gynecol* 41: 33, 1973
 72. SOMPOLINSKY D, SOLOMON F, ELKINA L, et al: Infections with mycoplasma and bacteria in induced mid-trimester abortion and fetal loss. *Am J Obstet Gynecol* 121: 610, 1975
 73. BRAUN P, LEE Y-H, KLEIN JO, et al: Birth weight and genital mycoplasmas in pregnancy. *N Engl J Med* 284: 167, 1971
 74. EMBREE JE, KRAUSE VW, EMBIL JA, et al: *Ureaplasma urealyticum*, *Mycoplasma hominis* and the placenta. *Obstet Gynecol* (in press)
 75. LAMEY JR, FOY HM, KENNY GE: Infection with *Mycoplasma hominis* and T-strains in the female genital tract. *Obstet Gynecol* 44: 703, 1974
 76. SHURIN PA, ALPERT S, ROSNER B, et al: Chorioamnionitis and colonization of the newborn infant with genital mycoplasmas. *N Engl J Med* 293: 5, 1975



Cortisporin Otic Drops A leader in the field of otological therapy.

Cortisporin* **Otic Drops**

(Polymyxin B-Neomycin-Hydrocortisone) Sterile

INDICATIONS: External otitis, otitis media with perforated tympanic membrane, infections of mastoidectomy and fenestration cavities.

CONTRAINDICATIONS: This product is contraindicated in tuberculous, fungal or viral lesions (herpes simplex, vaccinia and varicella) also in those individuals who have shown hypersensitivity to any of its components.

CAUTION: This product should be used with care in cases of perforated ear drum and in long-standing cases of chronic otitis media, because of the danger of ototoxicity. As with any antibiotic preparation, prolonged use may result in the overgrowth of non-susceptible organisms, including fungi. Appropriate measures should be taken if this occurs.

DOSAGE: 3 or 4 drops in ear 3 to 4 times daily or more frequently in acute conditions if required.

SUPPLIED: Each ml contains: polymyxin B sulfate 10,000 units, neomycin sulfate 5 mg, hydrocortisone 10 mg (1%) in sterile aqueous suspension. Available in 7 ml plastic dropper bottles.

Also available: CORTISPORIN Ointment 3.5 g tube.

Additional product information available on request.



Calmic Medical Division
Burroughs Wellcome Ltd.
LaSalle, Qué.

*Trade Mark



C-8001